新希望:蓝斑-去甲肾上腺素系统处于神经精神症状的交界点
阿尔茨海默病早期常以焦虑、激越、抑郁、强迫、食欲失调和睡眠障碍等神经精神症状为特征,常先于可测量的认知下降。临床和动物研究证据提示蓝斑-去甲肾上腺素系统过度活跃是这些行为的机制驱动因素。本文综述可能构成精神障碍基础的去甲肾上腺素能环路,以确定预防和延迟AD发病的治疗靶点。
要点
- AD早期NPS常先于认知下降,LC-NE过度活跃是候选机制。
- LC-NE环路涉及杏仁核、丘脑、下丘脑、前扣带回、前额叶和嗅觉区。
- 神经影像和生理测量可体内追踪LC完整性和NE传递,支持早期检测和靶向干预。
核心结论
- LC-NE系统过度活跃是早期AD神经精神症状的机制驱动因素,靶向该环路有望开发生物标志物驱动的分期特异性干预。
研究设计与样本
- 本文为综述,汇总临床和动物研究证据,聚焦去甲肾上腺素能环路与AD早期神经精神症状的关系。
主要发现
- AD最早阶段常以焦虑、激越、抑郁、强迫、食欲失调和睡眠障碍等NPS为特征,常先于可测量的认知下降。
- 临床和动物研究证据提示LC-NE系统过度活跃是这些行为的机制驱动因素。
- LC-NE过度活跃通过涉及杏仁核、丘脑、下丘脑、前扣带回、前额叶和嗅觉区的环路促进早期AD的NPS特征。
- 神经影像和生理测量进展使体内追踪LC完整性和NE传递成为可能,有助于早期检测LC-NE功能障碍。
临床怎么用
- 关注AD早期神经精神症状,将其视为潜在LC-NE功能障碍标志。
- 利用神经影像和生理测量早期检测LC-NE功能障碍,指导靶向药物和神经调控干预。
局限性
- 本文为综述,未报告原始研究样本量、效应量或置信区间等定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The earliest stages of Alzheimer's disease (AD) are frequently characterized by neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, compulsivity, appetite dysregulation, and sleep disturbances, often preceding measurable cognitive decline. Evidence from clinical and animal studies implicates hyperactivity of the locus coeruleus-norepinephrine (LC-NE) system as a mechanistic driver of these behaviors. Here, we review noradrenergic circuits that can potentially underlie psychiatric disturbances to identify therapeutic targets for preventing and delaying onset of AD. Given that this system influences attention, arousal, mood, and stress responses, LC-NE hyperactivity across circuitry involving amygdala, thalamus, hypothalamus, anterior cingulate cortex, prefrontal cortex, and olfactory areas can contribute to NPS features in early AD. Advances in neuroimaging and physiological measures of noradrenergic function have enabled in vivo tracking of LC integrity and NE transmission, offering the opportunity to detect LC-NE dysfunction early in disease progression and potentially implement targeted pharmacologic and neuromodulatory interventions to restore optimal LC-NE tone. Overall, dissection of LC-NE circuitry and its clinical translation hold promise for developing biomarker-driven, stage-specific interventions to reduce NPS burden and enhance the efficacy of disease-modifying therapies in AD.
引用
- Korukonda A, Weinshenker D. A new hope: locus coeruleus-norepinephrine system at the nexus of neuropsychiatric symptoms. Mol Psychiatry. 2026. PMID: 42332025. doi:10.1038/s41380-026-03696-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。